Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis

Table 2

Main characteristics of included studies.

Study		Patients	Design	Interventions	Primary endpoint
Small et al., 2006	127	CRPC	Randomized, double-blind, placebo-controlled	Sipuleucel-T, placebo	OS, TTP, reduction of PSA > 50%, AEs grade ≥ 3
Higano et al., 2009	98	CRPC	Randomized, double-blind, placebo-controlled	Sipuleucel-T, placebo
Kantoff et al., 2010	512	CRPC	Randomized, double-blind, placebo-controlled	Sipuleucel-T, placebo
Fizazi et al., 2012	1195	CRPC	Randomized, double-blind, placebo-controlled	Abiraterone acetate, placebo
Rathkopf et al., 2014	1088	CRPC	Randomized, double-blind, placebo-controlled	Abiraterone acetate, placebo
Scher et al., 2012	1199	CRPC	Randomized, double-blind, placebo-controlled	Enzalutamide, placebo
Beer and Tombal, 2014	1717	CRPC	Randomized, double-blind, placebo-controlled	Enzalutamide, placebo

CRPC: castration-resistant prostate cancer; OS: overall survival; TTP: time-to-progression; PSA: prostate-specific antigen; AEs: adverse events.